Press Releases

Webcast
Jounce Therapeutics, Inc. AACR Investor and Analyst Event
4/2/19 7:00 PM EDT
Date Title  
Mar 6, 2019
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with ipilimumab and with pembrolizumab - - Ended 2018 with $195.9 million in cash, cash equivalents and
Mar 4, 2019
CAMBRIDGE, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray , Ph.D., chief executive officer and
Feb 28, 2019
CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2018 financial
Feb 27, 2019
ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker ( ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday, April 2, 2019 CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc.
Jan 3, 2019
Dose Escalation Trial in Patients with Solid Tumors CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that the
Jan 2, 2019
CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray , Ph.D., chief